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Abstract
Background: Obesity is associated with both impaired testosterone production and a chronic state of low grade
inflammation. Previously it was believed that this inflammation was mediated by a decline in the immunosuppressive
action of testosterone. However, more recently an alternative hypothesis (GELDING theory) has suggested that
inflammation originating from the passage of intestinal bacteria into the circulation (metabolic endotoxaemia) may
actually be the cause of impaired testicular function in obese men. The aim of this study is to investigate if metabolic
endotoxaemia, as quantified by serum Lipopolysaccharide Binding Protein (LBP), is associated with impaired testicular
endocrine function.
Methods: A total of 50 men aged between 21 and 50 years (mean 35.1 ± 6.8 years) were assessed for adiposity (BMI,
waist circumference and % body fat using bio-impedance), inflammatory status (serum CRP, IL-1β, IL-6, TNFα and LBP)
and testicular endocrine function (serum testosterone, estradiol, AMH, LH and FSH). Statistical analysis was performed
using Pearson correlation analysis, with log transformation of data where appropriate, and multi-variate regression.
Results: Overall increasing adiposity (% body fat) was positively associated with metabolic endotoxaemia (LBP, r = 0.366,
p = 0.009) and inflammation (CRP r = 0.531, p < 0.001; IL-6 r = 0.463, p = 0.001), while also being negatively correlated
with serum testosterone (r = −0.403, p = 0.004). Serum testosterone levels were significantly negatively correlated with
inflammation (CRP r = −0.471, p = 0.001; IL-6 r = −0.516, p < 0.001) and endotoxaemia (LBP) after adjusting for serum LH
levels (p = −0.317, p = 0.03). Furthermore, serum IL-6 was negatively associated with AMH levels (r = −0.324, p = 0.023),
with a negative trend between LBP and AMH also approaching significance (r = −0.267, p = 0.064).
Conclusions: Obesity and its associated metabolic endotoxaemia helps initiate a pro-inflammatory state characterised
by raised serum IL-6 levels, which in turn is correlated with impairment of both Leydig (testosterone) and Sertoli cell
function (AMH). These results open up the potential for new treatments of obesity related male hypogonadism that
focus on preventing the endotoxaemia associated chronic inflammatory state.
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Contexte: L’obésité est associée à la fois à une altération de la production de testostérone et à un état chronique
d’inflammation de faible intensité. On pensait auparavant que cette inflammation était induite par une diminution
de l’action immunosuppressive de la testostérone. Une hypothèse alternative plus récente (la théorie GELDING) a
cependant suggéré que l’inflammation, qui a pour origine le passage de bactéries intestinales dans la circulation
(endotoxémie métabolique), pourrait être en fait la cause de l’altération de la fonction endocrine du testicule chez
les hommes obèses. Le but de la présente étude était de chercher si l’endotoxémie métabolique, évaluée par la
quantification sérique de la Protéine Liant les Lypopolysaccharides (LBP), était associée à une altération de la
fonction endocrine du testicule.
Matériel et Méthodes: Un total de 50 hommes âgés de 21 à 50 ans (moyenne 35,1 ± 6,8 ans) ont été évalué pour
l’adiposité (IMC, circonférence de la taille, et pourcentage de graisse corporelle par bio-impédance), le statut
inflammatoire (CRP, IL-1beta, IL-6, TNFalpha et LBP sériques) et la fonction endocrine du testicule (testostérone,
estradiol, AMH, LH et FSH sériques). L’analyse statistique des données a été réalisée par corrélation de Pearson -
après transformation logarithmique des données quand nécessaire – et régression multivariée.
Résultats: Une augmentation globale de l’adiposité (% de graisse corporelle) était positivement associée à
l’endotoxémie métabolique (LBP, r = 0.366, p = 0.009) et à l’inflammation (CRP r = 0.531, p < 0.001; IL-6 r = 0.463, p =
0.001), tout en étant également corrélée négativement à la testostérone sérique (r = −0.403, p = 0.004). Les taux de
testostérone sériques étaient, de façon significative, négativement corrélés à l’inflammation (CRP r = −0.471, p = 0.
001; IL-6 r = −0.516, p < 0.001) et à l’endotoxémie métabolique (LBP) après ajustement sur les taux de LH sériques
(p = −0.317, p = 0.03). L’IL-6 sérique était en outre négativement associée aux taux d’AMH (r = −0.324, p = 0.023),
avec une tendance négative entre LBP et AMH approchant la signification (r = −0.267, p = 0.064).
Conclusions: l’obésité et son endotoxémie métabolique associée favorisent l’initiation d’un état pro-inflammatoire
caractérisé par une élévation des taux d’IL-6 sériques, état qui est en retour corrélé à une altération des fonctions
des cellules de Leydig (testostérone) et de Sertoli (AMH). Ces résultats ouvrent la possibilité de nouveaux
traitements de l’hypogonadisme masculin lié à l’obésité, centrés sur la prévention de l’endotoxémie associée à l’état
inflammatoire chronique.
Mots-Clés: Mots-Clés, Obésité, Hypogonadisme, Endotoxine, Lipopolysaccharide (LPS), Testostérone, cellule de
Leydig, cellule de Sertoli
Background
Obesity is an increasing public health concern with ap-
proximately one third of men from developed countries
now being obese, and a further third overweight [1].
This increase in adiposity places men at increased risk of
metabolic disorders such as diabetes, hypertension and
hyperlipidaemia, but also impairs testosterone produc-
tion and spermatogenesis [2–5]. Hypo-androgenism is
associated with generalised depression and lethargy,
plus the more specific sexual symptoms of erectile dys-
function and diminished desire [6], all significantly redu-
cing men’s quality of life [2]. While weight loss usually
results in normalisation of androgen levels and sperm-
atogenesis [4, 7–9], unfortunately most obese men are
unable to achieve this goal and therefore continue to
suffer from the adverse effects of hypogonadism.
The current prevailing theory behind obesity related hypo-
gonadism is centered on adipose tissue aromatase activity
causing peripheral conversion of testosterone into estrogen
[3, 4], which exerts a negative feedback effect on pituitary
LH drive for testosterone production (central hypogonad-
ism). In addition, “heating” of the testicles by the enveloping
pelvic fat tissue [10], obesity related oxidative stress [11],
and adipokines such as Leptin [12] may also play a role in
perturbing testicular function in the obese man.
Multiple large epidemiological studies have reported sig-
nificant positive correlations between obesity and various
markers of inflammation (CRP, leukocyte count), yet nega-
tive associations between inflammation and serum testos-
terone [13–16]. This link between obesity, inflammation
and declining testosterone has primarily been considered
a result of withdrawal of testosterone’s immunosuppres-
sive effect [13–15], although some previous investigators
have also suggested that low grade inflammation may play
a direct role in hypogonadism [16, 17].
Recently we proposed in the GELDING theory that in-
flammation triggered by the passage of gut bacterial
endotoxin into the circulation of obese men may be re-
sponsible for impaired testosterone production [18]. The
human intestine contains trillions of bacteria bearing the
potent immune stimulant endotoxin (Lipopolysacchar-
ide, LPS) [19, 20]. Under normal conditions nutrients se-
lectively pass across the intestinal mucosal surface into
the circulation, while preventing trans-migration of gut
bacteria [21]. However, obesity and consumption of fatty
food are both associated with a breakdown in intestinal
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mucosal integrity that allows passage of gut bacteria into
the systemic circulation - so called “metabolic endotox-
aemia” [19–22]. The resulting chronic state of low grade
inflammation, typified by the production of pro-
inflammatory cytokines such as Il-1β, TNFα and IL-6,
has been reported to impair testicular steroidogenesis in
both animal and human interventional studies [23–25].
Given the observed links between inflammation and
hypogonadism, the underlying cause of inflammation in
these obese men is of considerable scientific and clinical
interest. Our recent proposal that endotoxin (lipopoly-
saccharide) derived from intestinal bacteria may trigger
impaired gonadal function is novel, and if proven correct
would open up new potential therapeutic strategies to
combat obesity related hypogonadism [18]. Therefore
the purpose of this study is to investigate the GELDING
hypothesis that metabolic endotoxaemia related inflam-
mation plays a significant role in impaired testicular
function in overweight/obese men.
Methods
Study cohort
Participants were men aged between 18 and 50 years of
age recruited from a private fertility clinic. Exclusion
criteria were documented inflammatory or infective
disease, the consumption of immune-suppressive medi-
cation (NSAID, corticosteroids, fish oil) or any hormonal
therapy (aromatase inhibitors, clomiphene citrate, hCG
or testosterone) in the last month.
Assessment of adiposity
Height was measured to within 1 cm using a stadiometer,
and weight (kg) and percentage body fat measured using
bio-impedance digital scales (Tanita, UM051) to the near-
est 0.1 kg and 0.1% respectively. Waist circumference was
measured using a tape measure placed midway between
the twelfth rib and the iliac crest to an accuracy of 0.5 cm.
Body mass index (BMI) was calculated as body weight
(kg) divided by height (m) squared. Men were classified as
lean (BMI 18.5–24.9 kg/m2), overweight (BMI 25–
29.9 kg/m2) or obese (BMI ≥ 30 kg/m2) as per WHO
guidelines [26].
Endocrine measurements
Blood was obtained by venepuncture between 8 and 10 am
for all participants. Serum was analysed for estradiol, testos-
terone,, AMH, SHBG, FSH and LH using an automated
chemiluminescence immunoassay (Cobas 6000 e 601,
Roche Diagnostics, USA), with the detectable ranges for
each hormone being 18.4–11010 pmol/L, 0.087–
52.0 nmol/L, 0.071–164.2 pmol/L, 0.350–200 nmol/L,, 0.1–
200 mIU/mL and 0.1–200 mIU/mL respectively. Calculated
free testosterone was determined using the Vermeulen
equation [27].
Assessment of metabolic endotoxaemia and immune
activation status
Metabolic endotoxaemia was quantified indirectly by
Lipopolysaccaride Binding Protein (LBP) analysis using
an ELISA according to the manufacturer’s guidelines
(Hycult, Uden, Netherlands), with the minimum detect-
able concentration of LBP being 4.4 ng/mL. Direct
measurement of endotoxin in plasma was not performed
because of the well-documented inaccuracies inherent
with these measurements [20, 28]. C-reactive protein
(CRP) was measured in serum using an automated che-
miluminesence machine (Integra 800, Roche Diagnos-
tics, USA), with the limit of detection being 1 mg/L.
Serum IL-1β, IL-6 and TNFα were analysed in duplicate
serum samples using a multiplex immunoassay (Procar-
taPlex kit, eBioscience). The detectable range for each of
these cytokines was 0.21–860 pg/ml, 1.06 – 4340 pg/ml
and 2.17 – 8900 pg/ml respectively.
Statistical analysis
Statistical analyses were conducted using Graphpad
Prism 7.01 (La Jolla, CA, USA) and IBM Statistical Prod-
uct and Service Solution software, version 23 (SPSS Inc.,
Chicago, IL, USA). Data was expressed as mean (±
standard deviation) when normally distributed, or as a
median (inter-quartile range) when not normally distrib-
uted on formal testing. Correlations were assessed using
the Pearson’s method, with log transformation of non-
normally distributed data prior to statistical analysis.
Multivariate analysis was performed with total and free
testosterone as the primary outcomes of interest to deter-
mine possible confounders effecting testosterone levels.
These confounders were then accounted for in a univari-
ate analysis examining the statistical relationship between
testosterone (total and free) and various markers of in-
flammation and body composition.
Results
The mean (± SD) age, BMI, percentage body fat and
waist circumference of participants was 35.1 ± 6.8 years,
26.96 ± 3.5 kg/m2, 23.6 ± 6% and 93.2 ± 9.5 cm respect-
ively. The endocrine and inflammatory status character-
istics of participants are summarised in Table 1. The
majority of participants were overweight (54%) or obese
(16%), with only 30% being of lean BMI. Adiposity sta-
tus, as assessed by BMI, waist circumference and per-
centage body fat, were all negatively correlated with
both total and calculated free testosterone levels (Fig. 1,
Table 2). Adiposity however was not significantly corre-
lated with any other reproductive hormone (estradiol,
LH, FSH, AMH) (Fig. 1, Table 2).
In terms of inflammatory status, all three measures of
adiposity (BMI, % body fat, waist circumference) were
positively correlated with serum IL-6 (Fig. 1, Table 2) and
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CRP, but not with IL1β or TNFα (Table 2). Serum LBP
was positively correlated with both adiposity (BMI
and % body fat) and serum IL-6 (Fig. 2). In relation
to CRP as an overall marker of inflammation, positive
correlations were observed between both CRP and
the cytokines IL1β and IL-6, but not with TNFα
(Table 2). CRP was negatively correlated with total
testosterone (r = −0.471, p = 0.001, Fig. 2), but not calcu-
lated free testosterone (R = −0.238, p = 0.11). Metabolic
endotoxaemia (LBP) was positively correlated with serum
LH (r = 0.334, p = 0.019) and significantly negatively co-
rrelated with testosterone concentration after adjusting
for serum LH levels (p = −0.317, p = 0.03). A significant
negative relationship between serum IL-6 and testosterone
(r = −0.516, p < 0.001, Fig. 3) was also observed.
Multi-variant regression analysis to determine the pre-
dictors of total testosterone resulted in two significant
models. In the strongest model IL-6, estrogen and SHBG
explained 51% of the variation, F (3,41) = 7.5, p = 0.009,
r2 = 0.51, while in the second model IL-6 and Estrogen
explained 43% of the variation, F (2,42) =9.7, p = 0.001,
r2 = 0.43. A further multi-variant analysis using free tes-
tosterone as the dependent variable resulted in 2 models.
In model 1 the use of IL-6 alone explained 15% of the
variation in free testosterone, F (1,44) = 9.0, p = 0.004, r2
= 0.15, whereas in model 2 IL-6 and estrogen explained
29% of the variation F (2,42) = 8.0, p = 0.001, r2 = 0.29.
In relation to Sertoli cell function, serum IL-6 was nega-
tively associated with serum AMH (r = −0.324, p = 0.023,
Fig. 3), with a negative trend between LBP and AMH ap-
proaching statistical significance (r = −0.267, p = 0.064).
Serum LBP was not significantly correlated with the indir-
ect marker of Sertoli cell function serum FSH.
Discussion
The principal finding of this study is that male adiposity
was associated with both metabolic endotoxaemia and
an increase in serum IL-6, with this heightened inflam-
matory response being associated with a decline in both
Leydig (testosterone) and Sertoli cell (AMH) function.
Several previous studies have also reported a similar
negative correlation between serum IL-6 and testoster-
one [16, 23, 29, 30], with the majority of these investiga-
tors suggesting that the observed increase in IL-6/
inflammation with obesity was due to a withdrawal of
testosterone’s immunosuppressive effect [13–15, 29, 30].
However, we believe that IL-6 may be directly inhibiting
testicular function, thereby leading to a reduction in tes-
tosterone and AMH levels. This suggestion is consistent
with earlier work in which the application of IL-6 to
Table 1 Participant inflammatory and endocrine characteristics
Variable Mean ± SD or Median (IQR)
CRP (mg/L) 1 (0.9–3)
IL-6 (pg/ml) 5.47 (4.29–6.5)
IL1β (pg/ml) 1.21 (1.06–1.31)
TNFα (pg/ml) 0.78 (0.63–0.92)
LBP (ng/ml) 10.39 (9.1–13.5)
Total Testosterone (nmol/L) 15.5 ± 5.0
Calculated Free testosterone (pmol/L) 298.3 ± 90.7
LH (IU/L) 4.8 ± 1.8
FSH (IU/L) 4.9 ± 2.4
AMH (pmol/L) 49.9 (37.7–77.3)
Estradiol (pmol/L) 77.0 ± 25.9
Fig. 1 Relationship between adiposity (% body fat) and male reproductive hormones
Tremellen et al. Basic and Clinical Andrology  (2017) 27:5 Page 4 of 9
rodent Leydig cells in vitro resulted in a decline in tes-
tosterone production, due to the inhibition of key ste-
roidogenic enzymes [31]. Furthermore, intra-venous
administration of recombinant IL-6 to healthy men has
been reported to result in a decline in serum testoster-
one [23]. Finally, it should be noted that administration
of testosterone replacement therapy to hypogonadal
men does not result in a decline in serum IL-6, thereby
weakening the existing prevailing argument that a reduc-
tion in testosterone’s immunosuppressive action is re-
sponsible for increased IL-6 levels [32, 33]. As such, we
believe it is more plausible that the negative relationship
between testosterone and IL-6 is produced by the cyto-
kine, directly inhibiting testosterone production.
Similar to our results, the NUMEVOX study of 229
overweight/obese men also reported a significant negative
correlation between serum IL-6 and bioavailable testoster-
one [16]. This group initially hypothesised those inflam-
matory mediators such as IL-6 may produce central
hypogonadism by up-regulating adipose aromatase activ-
ity, with the resulting estradiol reducing pituitary LH drive
for testosterone production, since pro-inflammatory cyto-
kines are known inducers of aromatase action. However,
the NUMEVOX study actually found no significant rela-
tionship between estradiol and testosterone levels, and
therefore it is unlikely that aromatisation is the primary
mechanism of hypogonadism in these obese men. Our
study also observed no correlation between BMI and serum
estradiol (r = 0.124, p = 0.39) or LH (r = 0.04, p = 0.77), des-
pite the presence of a significant negative correlation be-
tween BMI and serum testosterone (r = −0.306, p = 0.034),
which also suggests that aromatisation is unlikely to be the
dominant cause for obesity related hypogonadism. How-
ever, in our study cohort multi-variant analysis did identify
estradiol as a significant variable effecting both total and
free testosterone, thereby suggesting that estrogen does play
some small part in obesity related hypogonadism.
Importantly, our observation of a positive correlation
between endotoxaemia (LBP) and serum LH (r = 0.334,
p = 0.019) suggests a peripheral (testicular) cause for
obesity related hypogonadism, with a compensatory rise
in LH release in response to falling testosterone produc-
tion, rather than adipose aromatase/estradiol mediated
central hypogonadism. A similar trend of an increase in
serum LH accompanying a fall in serum testosterone fol-
lowing administration of rIL-6 to healthy male volun-
teers has previously been reported [23]. Interestingly,
administration of the pro-inflammatory cytokine IL-2
has also been reported to reduce testosterone produc-
tion in reproductive age men, primarily due to a com-
bination of a reduction in basal LH levels and testicular
responsiveness to LH [16]. However, since obesity is not



















Body fat (%) .844 .898 −0.403 .156 0.08 0.07 -.152 -.402 -.338 .531 .366 .463 .123 .207
BMI
(log)
.827 -.306 .124 0.04 .112 -.151 -.356 -.172 .498 .296 .379 .081 -.051
Waist
(cm)
-.310 .173 -.013 0.05 -.178 -.357 -.247 .432 .266 .424 .076 .084
Testo-
sterone
.334 .178 .012 -.128 .555 .700 -.471 -.244 -.516 -.253 -.191
E2 .052 .130 -.061 -.003 .218 -.007 .130 -.068 -.273 -.187
LH .380 -.283 .178 .084 .127 .334 .179 -.04 -.027
FSH
(log)
-.291 .208 -.172 .112 .140 .225 -.116 -.108
AMH
(log)
-.129 -.018 -.112 -.267 -.324 .299 .012
SHBG .137 -.253 -.207 -.344 -.082 -.035
cFT -.238 -.217 -.385 -.143 -.207
CRP
(log)
.369 .515 .302 0.015







Statistical analysis using Pearson correlation test. All values represent correlation coefficient value (r), with those reaching statistical significance (p < 0.05) being
indicated in bold type
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associated with increased serum IL-2 levels [34], the use
of IL-2 to replicate inflammatory processes seen in obes-
ity is probably not an inappropriate model to study
obesity related hypogonadism.
While our findings suggest that IL-6 has a greater in-
hibitory effect on the Leydig cells (decreased testoster-
one and increased LH) than Sertoli cell function, the
observed decline in serum AMH also suggests some
impairment of Sertoli cell function by IL-6. This finding
is consistent with previous publications, with reductions
in serum testosterone with increasing BMI being more
prominent than associated declines in markers of Sertoli
cell function, such as AMH or inhibin B [35]. These ob-
servations also make good physiological sense since the
Leydig cells are present within the testicular interstitium,
outside the blood-testis immunological barrier, and
therefore are in intimate contact with interstitial macro-
phages and serum cytokines [31]. Therefore macro-
phages and their neighbouring Leydig cells will be
exposed to any obesity related increase in serum IL-6,
which may in turn impair testosterone production. How-
ever the Sertoli cells are contained behind the blood
testis barrier [31], making them more resistant to the in-
hibitory action of circulatory IL-6. Secondly, as testoster-
one directly inhibits production of AMH [36], any
obesity related reduction in testosterone production is
likely to result in a reflex increase in AMH production,
potentially masking any obesity related impairment in
Sertoli cell function assessed by serum AMH.
This study is the first to provide supportive evidence for
the GELDING theory by linking metabolic endotoxaemia
with inflammation and impaired gonadal function in over-
weight and obese men. Our findings of a significant posi-
tive correlation between various markers of adiposity and
LBP is consistent with prior reports and confirms that in-
creasing adiposity is associated with metabolic endotoxae-
mia in our study cohort. Furthermore, the significant
positive correlation between serum LBP and IL-6 suggests
that metabolic endotoxaemia is likely to be a trigger for
IL-6 release, with IL-6 then directly inhibiting testicular
function. However we acknowledge that metabolic endo-
toxaemia is unlikely to be the sole cause of increased
serum IL-6 in obese men. A recent study has confirmed
that activated macrophages contained within adipose tis-
sue also are a significant source of IL-6 production [37].
We believe that gut derived endotoxin exposure may pro-
vide the initial “spark” that both initiates and then main-
tains the “flames of inflammation” within adipose tissue
macrophages- thereby maintaining high serum IL-6 levels.
Our earlier report of an increase in macrophage activity in
semen (seminal plasma neopterin) with increasing BMI is
consistent with our belief that obesity related inflamma-
tion can extend to the male reproductive tract [11].
We acknowledge several potential weaknesses in our
study. Firstly, this is only a pilot study of 50 men, with
16% of participants actually being obese. The recruit-
ment of a larger sample size with a greater proportion of
obese men is likely to produce more statistically rigorous
results. Secondly, while we have reported very significant
positive correlations between LBP and IL-6, and negative
correlations between IL-6 and testosterone levels, the
purely observational nature of our study does not enable
Fig. 2 Relationship between adiposity (% body fat) and
inflammation (LBP, IL-6)
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us to draw definitive cause-effect relationships. However,
given previous reports linking IL-6 exposure to impaired
testosterone production [16, 23, 29, 30], we do believe
that metabolic endotoxaemia related increase in IL-6
production is likely to play some role in impairing tes-
ticular function in obese men. We also acknowledge that
LBP is only an indirect measure of endotoxaemia and
the passage of gut bacteria derived endotoxin into the
circulation. Therefore studies that directly quantify obes-
ity related changes in intestinal permeability (e.g. sugar
absorption testing) and levels of endotoxin in the circu-
lation with markers of testicular function will be re-
quired to provide direct evidence for the GELDING
theory [18]. Finally, our study did not assess symptoms
of androgen deficiency, a worthwhile future endeavour,
as male wellbeing, not serum testosterone, is the primary
clinical end-point of interest.
A large body of scientific evidence has now linked low
levels of testosterone in men with an increase in the in-
cidence of cardiovascular disease [38, 39]. Previously this
adverse association had been explained by the common
co-morbidity of obesity, diabetes and hypertension in
hypogonadal men- all known risk factors for cardiovas-
cular disease. Interestingly, while testosterone replace-
ment therapy (TRT) has been reported to improve both
body composition (reduced fat and increased muscle
mass), and glucose metabolism in hypogonadal men
[40], the overwhelming majority of studies report that
androgen replacement does not result in a reduction in
cardiovascular disease, and even more alarmingly some
studies have reported an increased cardiovascular event
risk from TRT therapy [41]. Therefore could androgen
deficiency be an epi-phenomenon- associated with
cardiovascular disease but not the actual cause? Interest-
ingly endotoxaemia related inflammation has been sug-
gested to play a major role in the metabolic and
cardiovascular complications of obesity [18, 20, 38, 39],
and therefore it is possible that a more effective treat-
ment for obese men is to target endotoxaemia related
inflammation, rather than add back testosterone replace-
ment. Resolution of endotoxaemia may improve men’s
wellbeing by raising testosterone levels, while also redu-
cing cardiovascular events. Of course at present this is
still a hypothetical concept, but one well worth exploring
in the future.
According to the GELDING hypothesis [18], the key to
effective treatment of obesity related hypogonadism is to
improve the barrier function of the intestine, thereby pre-
venting trans-migration of endotoxin from the bowel
lumen into the circulation and lowering inflammation
known to impair testicular function. One potential treat-
ment that targets this process is the ingestion of probiotic
“good bacteria”. These beneficial microbes improve gut
wall integrity by releasing Short Chain Fatty Acids (SCFA)
that nourishes the adjacent mucosa, improving its barrier
integrity. Secondly probiotic bacteria complete for nutri-
ents with potentially pathogenic gram negative bacteria,
thereby reducing the endotoxin load within the intestine
[42]. A recent study supporting this “gut health” ap-
proach reported that ingestion of probiotic lactobacil-
lus reuteri bacteria resulted in an increase in Leydig
cell density and improvements in both serum testos-
terone and spermatogenesis in mice compared to
controls [43]. This beneficial effect of probiotics on male
reproductive function is most likely mediated by the im-
mune system, since blocking inflammation also resulted in
Fig. 3 Relationship between inflammation (IL-6, LBP) and endocrine function (testosterone, LH and AMH)
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a similar improvement in testosterone production and
spermatogenesis. To date no such studies have been con-
ducted in men, but the results of this study certainly sup-
port the possibility that this therapeutic approach may be
fruitful to investigate in the future.
Conclusions
The results of this study confirm that adiposity is associ-
ated with increasing levels of inflammation (serum CRP,
IL-6) and metabolic endotoxaemia (LBP), while also being
associated with a significant reduction in serum testoster-
one, independent of changes in serum gonadotrophins
(LH, FSH). Interestingly, serum IL-6 levels were also nega-
tively correlated with both serum testosterone and AMH,
raising the possibility that this key pro-inflammatory cyto-
kine may play a direct role in impairing Leydig and Sertoli
cell function. Furthermore, the observed positive correl-
ation between adiposity, metabolic endotoxaemia (LBP)
and serum IL-6 supports the possibility that endotoxin ex-
posure in obese men may be a significant trigger for in-
creased serum IL-6 production, which then in turn
impairs testicular function. While this observational study
cannot prove a direct causal link between obesity, in-
creased endotoxin exposure and male hypogonadism
(GELDING theory), it is the first human study to provide
indirect evidence supporting this link. Furthermore, these
results open up the potential for future new treatments
for obesity related male hypogonadism that focus on pre-
venting metabolic endotoxaemia and its associated
chronic inflammatory state.
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